PECAM1 and neoplasm: The results showed that the donafenib lipiodol group had a lower rate of tumor metastasis, a higher rate of tumor necrosis, a significantly reduced quantity of CD31-labeled tumor blood vessels, and promoted the infiltration of CD8+ T cells in the tumor area.